/ONCY
ONCY Stock - Oncolytics Biotech Inc.
Healthcare|BiotechnologyNASDAQ
$1.01+0.00%
+$0.00 (+0.00%) • Dec 19
67
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.61
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.85
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.11
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ONCY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.00 – $1.02
TARGET (TP)$1.16
STOP LOSS$0.93
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.88
52W High$1.51
52W Low$0.33
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $-298,587 | $-301,109 | $-360,575 | $-332,652 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-34,982,000 | $-25,036,175 | $-20,681,282 | $-20,925,470 | $-18,980,827 |
| Net Income | $-31,710,000 | $-20,561,804 | $-19,076,647 | $-20,980,772 | $-16,778,526 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.41 | $-0.41 | $-0.43 | $-0.49 | $-0.48 |
Company Overview
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
2 Bullish0 Neutral/Bearish
Price Targets
$5
Average Target
↑ 395.0% Upside
Now
$3
Low
$5
Average
$7
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 13th 2025 | Lake Street | Initiation | Buy | $7 |
| October 6th 2022 | Maxim Group | Initiation | Buy | $3 |
Earnings History & Surprises
ONCYBeat Rate
67%
Last 18 quarters
Avg Surprise
+11.7%
EPS vs Estimate
Beats / Misses
12/4
2 met exactly
Latest EPS
$-0.10
Q4 2025
EPS Surprise History
Q1 24
+63.6%
$-0.04vs$-0.11
Q2 24
+22.2%
$-0.07vs$-0.09
Q3 24
+12.5%
$-0.07vs$-0.08
Q4 24
-12.5%
$-0.09vs$-0.08
Q1 25
+12.5%
$-0.07vs$-0.08
Q2 25
+33.3%
$-0.06vs$-0.09
Q3 25
+54.5%
$-0.05vs$-0.11
Q4 25
+16.7%
$-0.10vs$-0.12
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q1 2026 | Mar 6, 2026 | $-0.06 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.12 | $-0.10 | +16.7% | ✓ BEAT |
Q3 2025 | Aug 8, 2025 | $-0.11 | $-0.05 | +54.5% | ✓ BEAT |
Q2 2025 | May 14, 2025 | $-0.09 | $-0.06 | +33.3% | ✓ BEAT |
Q1 2025 | Mar 7, 2025 | $-0.08 | $-0.07 | +12.5% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.08 | $-0.09 | -12.5% | ✗ MISS |
Q3 2024 | Aug 1, 2024 | $-0.08 | $-0.07 | +12.5% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.09 | $-0.07 | +22.2% | ✓ BEAT |
Q1 2024 | Mar 7, 2024 | $-0.11 | $-0.04 | +63.6% | ✓ BEAT |
Q4 2023 | Nov 3, 2023 | $-0.07 | $-0.10 | -42.9% | ✗ MISS |
Q3 2023 | Aug 14, 2023 | $-0.09 | $-0.09 | 0.0% | = MET |
Q2 2023 | May 5, 2023 | $-0.07 | $-0.07 | 0.0% | = MET |
Q1 2023 | Mar 3, 2023 | $-0.05 | $-0.10 | -100.0% | ✗ MISS |
Q4 2022 | Nov 7, 2022 | $-0.09 | $-0.06 | +33.3% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.09 | $-0.07 | +22.2% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $-0.13 | $-0.09 | +30.8% | ✓ BEAT |
Q1 2022 | Mar 3, 2022 | $-0.14 | $-0.11 | +21.4% | ✓ BEAT |
Q4 2021 | Nov 5, 2021 | $-0.15 | $-0.07 | +53.3% | ✓ BEAT |
Q3 2021 | Aug 6, 2021 | $-0.10 | $-0.11 | -10.0% | ✗ MISS |
Latest News
Oncolytics Biotech Announces Clinical And Translational Findings Supporting Development Of Pelareorep In Second-Line mCRC, Specifically In Patients With KRAS- MSS Disease
📈 PositiveBenzinga•Dec 16, 2025, 02:06 PM
Oncolytics Biotech Announces Alignments With U.S. FDA Regarding Design Of Pivotal Trial Of Pelareorep In Combination With Standard-Of-Care Therapy To Treat Metastatic Pancreatic Ductal Adenocarcinoma
📈 PositiveBenzinga•Nov 19, 2025, 02:02 PM
HC Wainwright & Co. Maintains Buy on Oncolytics Biotech, Raises Price Target to $10
📈 PositiveBenzinga•Nov 17, 2025, 12:16 PM
Oncolytics Biotech Announces Updated Results From Single-Arm SCAC Cohort Of GOBLET Study Evaluating Pelareorep In Combination With Atezolizumab In Patients With ≥2L Metastatic SCAC
📈 PositiveBenzinga•Oct 28, 2025, 11:35 AM
Oncolytics Biotech Plans Move From Canada To U.S. With Proposed Domestication To Nevada
➖ NeutralBenzinga•Oct 20, 2025, 01:12 PM
Oncolytics Biotech Files For Common Stock Offering Of $50M
📉 NegativeBenzinga•Oct 17, 2025, 08:49 PM
Oncolytics Biotech Updates GOBLET Trial: Pelareorep Shows Strong Efficacy In GI Cancers, Expands To U.S. Sites; Key Data Readouts Expected Q4 2025 And Q1 2026
📈 PositiveBenzinga•Sep 16, 2025, 11:06 AM
Oncolytics Biotech shares are trading higher after the company announced clinical and translational data from three metastatic colorectal cancer studies demonstrating consistent efficacy signals, immune activation, and survival outcomes that exceed historical benchmarks in multiple mCRC treatment settings.
📈 PositiveBenzinga•Sep 8, 2025, 04:31 PM
Oncolytics Biotech Reports Pelareorep Boosts Survival In Colorectal Cancer Patients
📈 PositiveBenzinga•Sep 8, 2025, 11:10 AM
Oncolytics Updates Pelareorep Safety Analysis; Says Data Continue To Demonstrate Favorable Safety Profile For Pelareorep Across Multiple Indications And In Combination With Multiple Treatments
📈 PositiveBenzinga•Sep 2, 2025, 01:13 PM
Oncolytics Biotech Files For Mixed Shelf Offering Of Up To $150M
➖ NeutralBenzinga•Aug 22, 2025, 09:25 PM
Frequently Asked Questions about ONCY
What is ONCY's current stock price?
Oncolytics Biotech Inc. (ONCY) is currently trading at $1.01 per share. The stock has moved +0.00% today.
What is the analyst price target for ONCY?
No analyst price targets are currently available for this stock.
What sector is Oncolytics Biotech Inc. in?
Oncolytics Biotech Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ONCY's market cap?
Oncolytics Biotech Inc. has a market capitalization of $0.10 billion, making it a small-cap company.
Does ONCY pay dividends?
No, Oncolytics Biotech Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorATOS
Atossa Therapeutics, Inc.
$0.73
Mkt Cap: $0.1B
CLNN
Clene Inc.
$6.68
Mkt Cap: $0.1B
COYA
Coya Therapeutics, Inc.
$5.49
Mkt Cap: $0.1B
IMMX
Immix Biopharma, Inc.
$5.72
Mkt Cap: $0.2B
MGNX
MacroGenics, Inc.
$1.50
Mkt Cap: $0.1B
SRZN
Surrozen, Inc.
$21.76
Mkt Cap: $0.2B
TIL
Instil Bio, Inc.
$11.27
Mkt Cap: $0.1B
TVGN
Tevogen Bio Holdings Inc.
$0.38
Mkt Cap: $0.1B
WHWK
Whitehawk Therapeutics Inc
$2.56
Mkt Cap: $0.1B
ZNTL
Zentalis Pharmaceuticals, Inc.
$1.40
Mkt Cap: $0.1B
Explore stocks similar to ONCY for comparison